| Literature DB >> 33169719 |
Navisa Sadat Seyedghasemi1,2, Abbas Bahrampour1,2,3, Abbas Etminan4, AliAkbar Haghdoost5, Mohammad Reza Baneshi6.
Abstract
BACKGROUND: Information regarding the prognosis and burden of diseases can be used by policymakers to determine competing health priorities. We aimed to assess the Relative Survival Rate (RSR) and loss of expectation of life (LEL) to evaluate the prognosis and burden of diseases in Hemodialysis (HD) patients. STUDYEntities:
Keywords: Hemodialysis; Life Expectancy; Prognosis; Survival
Mesh:
Year: 2020 PMID: 33169719 PMCID: PMC7585771 DOI: 10.34172/jrhs.2020.21
Source DB: PubMed Journal: J Res Health Sci ISSN: 2228-7795
Relative survival rate, Life expectancy, and loss in expectation of life for patients who began hemodialysis between March 2008 and January 2019 in Kerman City, Iran
|
|
|
|
|
|
| |
|
|
| |||||
| Age (yr) | ||||||
| 18-35 | 28.4 ±4.4 | 0.76 (0.58, 0.93) | 0.3 | 61.1 | 45.87 (36.6, 55.1) | 15.26 |
| 36-45 | 41.2 ±2.8 | 0.69 (0.47, 0.92) | 0.5 | 50.2 | 35.58 (25.4, 45.8) | 14.63 |
| 46-55 | 51.1 ±2.7 | 0.63 (0.48, 0.78) | 1.0 | 40.2 | 25.78 (19.9, 31.7) | 14.38 |
| 56-65 | 60.4 ±2.8 | 0.59 (0.48, 0.72) | 2.1 | 32.0 | 20.05 (16.8, 23.3) | 11.98 |
| ≥66 | 73 ±6.0 | 0.45 (0.33, 0.57) | 4.8 | 23.2 | 12.20 (10.6, 15.5) | 11.01 |
| Sex | ||||||
| Female | 57.6 ±14.6 | 0.54 (0.43, 0.65) | 2.2 | 35.2 | 19.61 (16.4, 22.8) | 15.56 |
| Male | 58.7 ±15.3 | 0.58 (0.50, 0.66) | 3.0 | 34.8 | 21.29 (18.9, 23.7) | 13.47 |
| Diabetes status | ||||||
| Diabetics | 62.1 ±11.3 | 0.53 (0.44, 0.62) | 2.9 | 31.6 | 18.66 (16.0, 21.3) | 12.95 |
| Non-diabetics | 53.0 ±17.7 | 0.61 (0.52, 0.70) | 2.4 | 39.5 | 27.68 (24.2, 31.2) | 11.79 |
| Total | 58.3 ±15.0 | 0.57 (0.50, 0.63) | 2.7 | 34.9 | 22.56 (20.4, 24.7) | 12.36 |
a Percentage of deaths from causes other than those associated with or due to hemodialysis at 5th year of follow up; 5-year RSR minus 5-year survival rates
Baseline characteristics of patient, result of Kaplan Meier analysis, and estimation of model parameters Cox extended with g (t) = t in patients who began hemodialysis between March 2008 to January 2019 in Kerman City, Iran
|
|
|
|
|
|
|
|
| Total | 648 (100) | 6.4 (6) | 0.54 | 0.171 | ||
| Sex | ||||||
| Male | 395 (61.0) | 6.6(6) | 0.55 | - | 1.00 | |
| Female | 253 (39.0) | 5.8 (5) | 0.52 | 0.080 | 1.09 (0.83, 1.43) | 0.557 |
| Age group (yr) | ||||||
| 18-34 | 69 (10.6) | 6.5 (-) | 0.76 | - | 1.00 | |
| 35-44 | 56 (8.6) | 6.5 (-) | 0.69 | 0.278 | 1.23 (0.53, 2.85) | 0.627 |
| 45-54 | 104 (16.0) | 6 (-) | 0.62 | 0.581 | 1.75 (0.86, 3.57) | 0.123 |
| 55-64 | 192 (29.6) | 5.7 (6) | 0.57 | 0.549 | 2.16 (1.12, 4.18) | 0.021 |
| ≥65 | 227 (35.2) | 4.4 (4) | 0.40 | 0.425 | 3.24 (1.71, 6.17) | 0.001 |
| Diabetes status | ||||||
| Non-diabetics | 273 (42.1) | 7.03 (-) | 0.59 | - | 1.00 | |
| Diabetics | 375 (57.9) | 5.74 (5) | 0.50 | 0.027 | 0.6 (0.38, 0.95) | 0.029 |
| Diabetes status×t | - | - | - | - | 1.3 (1.08, 1.54) | 0.005 |
| Blood group a | ||||||
| O | 230 (36.6) | 6.3 (6) | 0.52 | - | 1.00 | |
| A | 179 (28.5) | 7.2 (-) | 0.57 | 0.380 | 0.89 (0.62, 1.27) | 0.524 |
| B | 166 (26.4) | 6.0 (5) | 0.43 | 0.788 | 1.33 (0.95, 1.85) | 0.094 |
| AB | 53 (8.4) | 5.1 (4) | 0.34 | 0.534 | 1.36 (0.85, 2.16) | 0.195 |
a Median for subgroups whose survival rate was no less than 0.5, it is impossible to calculate the median survival time.
Figure 1
Figure 2
Figure 3